Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

@article{Wessels2008RecentII,
  title={Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.},
  author={J. Wessels and T. Huizinga and H. Guchelaar},
  journal={Rheumatology},
  year={2008},
  volume={47 3},
  pages={
          249-55
        }
}
This review presents recent data supporting the methotrexate (MTX) mechanisms of action, which are likely to account for its anti-proliferative and immunosuppressive effects in rheumatoid arthritis (RA). The effects of MTX in vivo may be mediated by reducing cell proliferation, increasing the rate of apoptosis of T cells, increasing endogenous adenosine release, altering the expression of cellular adhesion molecules, influencing production of cytokines, humoral responses and bone formation… Expand
Folates and antifolates in rheumatoid arthritis
Abstract Almost all current standard treatment of care for patients with chronic inflammatory diseases such as rheumatoid arthritis (RA) includes the folate antagonist methotrexate (MTX). Despite theExpand
Current Understanding of Rheumatoid Arthritis Therapy
TLDR
This review summarizes the pathogenesis‐related rationales for the current therapeutic strategies in RA and for emerging therapies and potential approaches to restoring immune tolerance in RA. Expand
An update on methotrexate
TLDR
Methotrexate was shown to improve signs and symptoms of RA, disease activity and function, to a similar degree as the tumor necrosis factor blockers, and it inhibits radiographic progression to a smaller degree than the antitumor Necrosis factor agents. Expand
Current and future role of methotrexate in the therapeutic armamentarium for rheumatoid arthritis
TLDR
Methotrexate seems to be one of the safest DMARDs, while there is evidence that patients treated with MTX have lower mortality, especially due to cardiovascular causes. Expand
The future of folic acid antagonist therapy in rheumatoid arthritis.
  • C. Fiehn
  • Medicine
  • Arthritis and rheumatism
  • 2009
TLDR
It should be emphasized that MTX is experiencing a comeback in RA clinical trials, although this drug has several pharmacologic disadvantages that one might think should be limiting its use. Expand
Markers of Treatment Response to Methotrexate in Rheumatoid Arthritis: Where Do We Stand?
TLDR
An update is provided on the current data regarding biomarkers of treatment response to MTX and the role of potential biomarkers in predicting treatment effectiveness of MTX. Expand
Pharmacokinetic consideration of synthetic DMARDs in rheumatoid arthritis
TLDR
A need to rationalize the use of synthetic DMARDs to help improve RA treatment by the construction of suitable models of the disease process, thereby augmenting treatment options and integrating pharmacokinetic and pharmacodynamic properties into this model will help in improving treatment outcomes. Expand
Systemic methotrexate for the treatment of psoriasis
TLDR
An extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics is made. Expand
Effects of methotrexate on the expression of the translational isoforms of glucocorticoid receptors α and β: correlation with methotrexate efficacy in rheumatoid arthritis patients.
TLDR
MTX in vitro induces greater expression of GRαAB isoform in PBMC from RA patients who later respond to MTX treatment than in non-responding patients, which may have clinical applications for predicting MTX efficacy in RA patients. Expand
Auxiliary in vitro and in vivo biological evaluation of hydrogen peroxide sensitive prodrugs of methotrexate and aminopterin for the treatment of rheumatoid arthritis.
TLDR
It is found that prodrug 1, an arylboronic acid ROS-sensitive MTX-prodrug, displays similar in vivo efficacy as MTX at an equimolar dose, while avoiding adverse effects known to restrict MTX treatment. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 71 REFERENCES
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
TLDR
The mechanism of action of methotrexate, originally developed as a folate antagonist for the treatment of cancer, and its role in the therapy of rheumatoid arthritis are reviewed. Expand
Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis
TLDR
Several lines of evidence clearly suggest that MTX does not act simply as a cytotoxic (antiproliferative) agent for the cells responsible for the joint inflammation in RA. Expand
Two Inhibitors of DNA‐Synthesis Lead to Inhibition of Cytokine Production via a Different Mechanism
TLDR
T‐cells are the main target cells of the immunosuppressive drugs MPA and MTX, and the production of T‐cell cytokines was inhibited by both drugs. Expand
The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules.
TLDR
It is shown that MTX caused a dose-dependent suppression of T cell activation and adhesion molecule expression, and this was not due to lymphocyte apoptosis, and these mechanisms are important mechanisms in the anti-inflammatory action of MTX. Expand
Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis.
TLDR
There is strong evidence that adenosine mediates the antiinflammatory effects of MTX in this model of RA, and the findings suggest that abstinence from caffeine, a ubiquitous food additive and medication, may enhance the therapeutic effects ofMTX in RA. Expand
Methotrexate in the treatment of rheumatoid arthritis. I. In vitro effects on cells of the osteoblast lineage.
TLDR
Treatment with MTX inhibits the proliferation of primitive marrow stromal cells, but not their ability to undergo osteogenic differentiation, and these findings are reassuring for clinicians using MTX in the treatment of RA. Expand
Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis.
TLDR
It is shown that there is no impact of effective MTX dose represented by EMTX on blood adenosine concentration in JIA patients and it is likely that local release ofadenosine at inflamed tissues is responsible for its action which may not be reflected by sustained increase of its blood concentration. Expand
Lack of evidence for inhibition of angiogenesis as a central mechanism of the antiarthritic effect of methotrexate
TLDR
Data support the hypothesis that inhibition of angiogenesis does not significantly contribute to the antiarthritic effect of MTX seen in patients and animal models for RA and the combination ofMTX with antiangiogenic drugs appears to be a rational strategy in the treatment of RA. Expand
Genetically based resistance to the antiinflammatory effects of methotrexate in the air-pouch model of acute inflammation.
TLDR
Genetic factors contribute to the antiinflammatory efficacy of MTX, and a single locus involved in MTX-induced adenosine up-regulation is likely responsible for the observed resistance to MTX in DBA/1J mice. Expand
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
TLDR
The differential effect on IFNgamma and IL6 production supports the hypothesis that activated T cells are preferentially inhibited by leflunomide. Expand
...
1
2
3
4
5
...